.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
Medtronic
Mallinckrodt
Johnson and Johnson
Julphar
McKesson
Cerilliant
UBS
Cantor Fitzgerald

Generated: July 26, 2017

DrugPatentWatch Database Preview

OMONTYS PRESERVATIVE FREE Drug Profile

« Back to Dashboard

Which patents cover Omontys Preservative Free, and what generic Omontys Preservative Free alternatives are available?

Omontys Preservative Free is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and six patent family members in thirty-two countries.

The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Summary for Tradename: OMONTYS PRESERVATIVE FREE

Patents:6
Applicants:1
NDAs:1
Clinical Trials: see list9,065
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OMONTYS PRESERVATIVE FREE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-006Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-004Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OMONTYS PRESERVATIVE FREE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,906,485Erythropoietin receptor peptide formulations and uses► Subscribe
7,855,175Peptides that bind to the erythropoietin receptor► Subscribe
8,304,391Peptides that bind to the erythropoietin receptor► Subscribe
8,592,365Spacer moiety for poly(ethylene glycol) modified peptide based compounds► Subscribe
8,324,159Erythropoietin receptor peptide formulations and uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OMONTYS PRESERVATIVE FREE

Country Document Number Estimated Expiration
New Zealand543935► Subscribe
Eurasian Patent Organization200501798► Subscribe
CroatiaP20120989► Subscribe
Japan2009108061► Subscribe
European Patent Office2195002► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Argus Health
Cantor Fitzgerald
Farmers Insurance
Merck
Fish and Richardson
Citi
Johnson and Johnson
McKinsey
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot